

Accepted Manuscript

Title: Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy

Authors: Ana Brotons-Canto, Carlos Gamazo, Nekane Martín-Arbella, Muthanna Abdulkarim, Jose Matías, Mark Gumbleton, Juan M. Irache



PII: S0141-8130(17)33074-X
DOI: <https://doi.org/10.1016/j.ijbiomac.2017.09.109>
Reference: BIOMAC 8286

To appear in: *International Journal of Biological Macromolecules*

Received date: 24-8-2017
Accepted date: 27-9-2017

Please cite this article as: Ana Brotons-Canto, Carlos Gamazo, Nekane Martín-Arbella, Muthanna Abdulkarim, Jose Matías, Mark Gumbleton, Juan M. Irache, Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy, *International Journal of Biological Macromolecules* <https://doi.org/10.1016/j.ijbiomac.2017.09.109>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy

Ana Brotons-Canto¹, Carlos Gamazo², Nekane Martín-Arbella¹, Muthanna Abdulkarim³, Jose Matías⁴, Mark Gumbleton³, Juan M. Irache¹

¹Department of Pharmacy and Pharmaceutical Technology, University of Navarra, 31008, Pamplona, Spain.

²Department of Microbiology, University of Navarra, 31008, Pamplona, Spain

³School of Pharmacy and Pharmaceutical Science, Cardiff University, Cardiff, UK.

Corresponding author

Juan M. Irache

Dep. Pharmacy and Pharmaceutical Technology

University of Navarra

C/Irunlarrea 1

31080 – Pamplona

Spain

Tel: +34948425600

e-mail: jmirache@unav.es

Abstract

The aim of this work was to evaluate the potential application of an original oral immunotherapy, based on the use of nanoparticles, against an experimentally induced peanut allergy. In this context, a roasted peanut extract, containing the main allergenic proteins, were encapsulated into poly(anhydride) nanoparticles. The resulting devices (PE-NP) displayed a mean size of about 150 nm and a significantly lower surface hydrophobicity than empty nanoparticles (NP). This low hydrophobicity correlated well with a higher in vitro diffusion in pig intestinal mucus than NP and an important in vivo capability to reach the intestinal epithelium and Peyer's patches.

The immunotherapeutic capability of PE-NP was evaluated in a model of pre-sensitized CD1 mice to peanut. After completing therapy of three doses of peanut extract, either free or encapsulated into nanoparticles, mice underwent an intraperitoneal challenge.

Download English Version:

<https://daneshyari.com/en/article/8327975>

Download Persian Version:

<https://daneshyari.com/article/8327975>

[Daneshyari.com](https://daneshyari.com)